AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 subvariant, in an independent lab study.
Data from the study by the Washington University showed the therapy reduced the amount of virus detected in samples of all tested Omicron subvariants in mice lungs, the London-listed drugmaker said on Monday. The study has yet to be peer reviewed.
"The findings further support Evusheld as a potential important option to help protect vulnerable patients such as the immunocompromised who could face poor outcomes if they were to become infected with COVID-19," senior AstraZeneca executive John Perez said.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Some children, teenagers retain natural COVID-19 antibodies for months: studyA new study out of the United States has found evidence to suggest some children and teenagers previously infected with COVID-19 develop natural antibodies that can last for months.
Read more »
Ontario reports total of 613 people in hospital with COVID-19, including 185 in ICU
Read more »
Ontario reports total of 551 people in hospital with COVID-19, including 182 in ICU
Read more »
COVID-19 mask mandate lifts in Ontario for most settings | Globalnews.caAs of Monday, individuals are no longer required by the province to wear a mask in most settings.
Read more »
Vaccinated travellers won't need COVID-19 test to enter Canada as of April 1ICYMI: Vaccinated travellers won't need COVID-19 test to enter Canada as of April 1 — via financialpost vaccine COVID19 travel Canada
Read more »